Aim of the Study: In two institutions, a retrospective analysis was performed on patients with histologically proven locally advanced pancreatic cancer without distant metastases. The aim of this analysis is to assess whether chemoradiotherapy provides survival benefit for patients with locally advanced pancreatic cancer. Methods: Forty-five patients from the Erasmus Medical Centre (Erasmus MC), Rotterdam, received 5-fluorouracil (5-FU) and radiotherapy and, 38 patients from the Academic Medical Centre Amsterdam (AMC) were offered the best supportive care. Radiotherapy consisted of 50 Gy external upper abdomen radiation in two courses, concomitant with intravenous 5-FU 25 mg/kg/ 24 h continuously on the first 4 days of each treatment course. Results: The treatment protocol was completed in 38 of 45 patients (84%) without complications. Radiological response was evaluated in 38 patients. Ten patients (26%) showed a partial response, stable disease was seen in 6 (16%) patients and progressive disease in 22 (58%) patients. A second-look operation was performed in 8 of 10 patients (72%) showing a radiological response, in 3 patients the tumour could be resected. Median overall survival time for the Erasmus MC group (n = 45) was 9.8 months compared to 7.6 months when the best supportive care was given (AMC group, p = 0.04). Conclusion: Although overall survival remains poor, treatment with 5-FU and radiotherapy might benefit some patients with locally advanced pancreatic cancer.

Keywords:
Pancreatic cancer, 5-Fluorouracil, Neoadjuvant treatment
1.
Bramhall SR, Allum WH, Jones AG, et al: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995;82:111–115.
2.
Warshaw AL, Gu ZY, Wittenberg J, Waltman AC: Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990;125:230–233.
3.
Jeekel J, Treurniet-Donker AD: Treatment perspectives in locally advanced unresectable pancreatic cancer. Br J Surg 1991;78:1332–1334.
4.
Gastrointestinal Tumor Study Group: A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. Ann Surg 1979;189:205–208.
5.
Gastrointestinal Tumor Study Group: Therapy of locally advanced unresectable pancreatic cancer: a randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5-fluorouracil). Cancer 1981;48:1705–1710.
6.
Rich TA, Evans DB: Preoperative combined modality therapy for pancreatic cancer. World J Surg 1995;19:264–269.
7.
Bajetta E, Di Bartolomeo M, Stani SC, et al: Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys 1999;45:285–289.
8.
Boz G, De Paoli A, Innocente R, et al: Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2001;51:736–740.
9.
Ceha HM, van Tienhoven G, Gouma DJ, et al: Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000;89:2222–2229.
10.
Ishii H, Okada S, Tokuuye K, et al: Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516–1520.
11.
Mehta VK, Poen JC, Ford JM, et al: Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 2001;24:155–159.
12.
Shinchi H, Takao S, Noma H, et al: Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002;53:146–150.
13.
Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 2000;89:314–327.
14.
White R, Lee C, Anscher M, et al: Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol 1999;6:38–45.
15.
van Geenen RC, Keyzer-Dekker CM, van Tienhoven G, Obertop H, Gouma DJ: Pain management of patients with unresectable peripancreatic carcinoma. World J Surg 2002;26:715–720.
16.
Japanese Pancreatic Society: General Rules for the Study of Pancreatic Cancer. Tokyo, Kanehara, 1993, pp 25–35.
17.
Kuhlmann KF, de Castro SM, Wesseling JG, et al: Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549–558.
18.
Treurniet-Donker AD, van Mierlo MJ, van Putten WL: Localized unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 1990;18:59–62.
19.
Fisher BJ, Perera FE, Kocha W, et al: Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1999;45:291–295.
20.
Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG: Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil – an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373–378.
21.
Komaki R, Wadler S, Peters T, et al: High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801). Cancer 1992;69:2807–2812.
22.
Paulino AC, Latona C: Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. Cancer Invest 2000;18:309–313.
23.
Seydel HG, Stablein DM, Leichman LP, Kinzie JJ, Thomas PR: Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience. Cancer 1990;65:1478–1482.
24.
Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006–2010.
25.
Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751–755.
26.
Pilepich MV, Miller HH: Preoperative irradiation in carcinoma of the pancreas. Cancer 1980;46:1945–1949.
27.
Poen JC, Ford JM, Niederhuber JE: Chemoradiotherapy in the management of localized tumors of the pancreas. Ann Surg Oncol 1999;6:117–122.
28.
Van Heek NT, DeCastro SM, van Eijck CH, van Geenen RC, Hesselinkk EJ, Breslau PJ, Tran TC, Kazemier G, Visser MR, Busch OR, Obertop H, Gouma DJ: The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life. Ann Surg 2003;238:894–902.
29.
Van Heek, van Geenen RC, Busch OR, Gouma DJ: Palliative treatment in peri-pancreatic carcinoma: stenting or surgical therapy? Acta Gastroenterol Belg 2002;65:171–175.
30.
Azria D, Ychou M, Jacot W, et al: Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 2002;25:360–365.
31.
Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer 2002;94:902–910.
32.
Ducreux M, Rougier P, Pignon JP, et al: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002;13:1185–1191.
33.
Furuse J, Kinoshita T, Kawashima M, et al: Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer 2003;97:1346–1352.
34.
Mawdsley S, Hall M, Glynne-Jones R: Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil. Clin Oncol (R Coll Radiol ) 2002;14:308–312.
35.
Osti MF, Costa AM, Bianciardi F, et al: Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study. Tumori 2001;87:398–401.
36.
Kastl S, Brunner T, Herrmann O, et al: Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas. Eur J Surg Oncol 2000;26:578–582.
37.
Jessup JM, Steele G Jr, Mayer RJ, et al: Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993;128:559–564.
38.
de Lange SM, van Groeningen CJ, Meijer OW, et al: Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. Eur J Cancer 2002;38:1212–1217.
39.
Pisters PW, Abbruzzese JL, Janjan NA, et al: Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998;16:3843–3850.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.